Trials / Completed
CompletedNCT01915823
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages >4 Years to <12 Years With Seasonal Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 348 (actual)
- Sponsor
- Meda Pharmaceuticals · Industry
- Sex
- All
- Age
- 4 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to \<12 years old who have seasonal allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | azelastine hydrochloride and fluticasone propionate | |
| DRUG | Dymista vehicle |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-02-01
- First posted
- 2013-08-05
- Last updated
- 2015-06-29
- Results posted
- 2015-06-29
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01915823. Inclusion in this directory is not an endorsement.